{"name":"Soleno Therapeutics","slug":"soleno","ticker":"SLNO","exchange":"NASDAQ","domain":"soleno.life","description":"Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.","hq":"Redwood City, CA","founded":0,"employees":"182","ceo":"Anish Bhatnagar","sector":"Rare Disease / Endocrinology","stockPrice":52.99,"stockChange":0.04,"stockChangePercent":0.08,"marketCap":"$2.8B","metrics":{"revenue":285008000,"revenueGrowth":138.8,"grossMargin":98.6,"rdSpend":40627000,"netIncome":20890000,"cash":255599008,"dividendYield":0,"peRatio":27.5,"fiscalYear":"FY2016"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Placebo for DCCR","genericName":"Placebo for DCCR","slug":"placebo-for-dccr","indication":"DCCR-related conditions","status":"phase_3"},{"name":"VYKAT XR","genericName":"VYKAT XR","slug":"vykat-xr","indication":"Hypokalemia (low serum potassium)","status":"marketed"}]}],"pipeline":[{"name":"Placebo for DCCR","genericName":"Placebo for DCCR","slug":"placebo-for-dccr","phase":"phase_3","mechanism":"This drug is a placebo for DCCR, meaning it has no active therapeutic effect.","indications":["DCCR-related conditions"],"catalyst":""},{"name":"VYKAT XR","genericName":"VYKAT XR","slug":"vykat-xr","phase":"marketed","mechanism":"VYKAT XR is a sustained-release formulation of potassium that provides controlled delivery of potassium to treat hypokalemia.","indications":["Hypokalemia (low serum potassium)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Soleno Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Soleno reported its Q4 and full-year 2023 financial results, including revenue and net loss.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Soleno Therapeutics Announces $10 Million Registered Direct Offering","summary":"Soleno announced a registered direct offering to raise $10 million in gross proceeds.","drugName":"","sentiment":"negative"},{"date":"2023-08-01","type":"regulatory","headline":"Soleno Therapeutics Receives Complete Response Letter from FDA for DCCR New Drug Application","summary":"Soleno received a CRL from the FDA for its DCCR NDA, requiring additional information.","drugName":"","sentiment":"negative"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQVHM2TTdSWjZEb0JvQkRveFYwc1RyRGxNVEVJSXNvTXRJRmNfc0NSa0YzT0VEN0VRSHpNbWktZ0VpU01kNm9XZHRvRFBMVXpvTW9mZWlTWklodFU4ZG4yODcyY1UybHU5TVNkajF0MjlkdWFuNUJVSy00WlJtR2l6NFllZGRMUkFlWTRoU01HaTBITmdBdXdsWWpWd3hhdFpLRy1OM01lNUs?oc=5","date":"2026-04-07","type":"deal","source":"The Pharma Letter","summary":"Neurocrine expands portfolio with buy of Soleno Therapeutics - The Pharma Letter","headline":"Neurocrine expands portfolio with buy of Soleno Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxOMUcwSDU2R0VWd0Q3MWRoY25QM3ByWkctQThhWVZWTzE1cm1weEJkd25OZlVKdWc1eXhqZkItdHZuRExFbEI0TklTcnhsR0RZZHJUQVlrellfR3B4b3FyZ3NCSTl0SVU0dDY5QzVyc3JnX2VQc0JfTElESkliWGNDQjMtSzlMZ21ibUNkaks0aUtZa1REQmFqbmJZRy1OMThmTzZSZkx1Um1Kdm5oNTdTcXJjdFYzMFVHcVg4UnlWVE0yZlBCWW5QR1g4NExsSzFtWnk4UjAzckdxT0IyamhRbnpHTXdKR1R2UHViSTR6UGx4bjlHZGMtWGNDOTd0SDdKbnVQeldZTDRFUnp5Ump0MUJxcDhDNktDcXc?oc=5","date":"2026-04-07","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOOXpSWmt2MXJsV1dMM0gzQlZ3emVYa05Mdk9nUHR2Wk1VVmVUbXBsYy1zRnR5V0ZZUDc4M3dFemdyUjdtcTduX09fMW5oS3J1NDFTd2F5WEdXdElQNDhScGhrb0ZBcDlHWVktR0o3ME9DNzFJb3JFSVdJSGpqWGlZaVdKUlBhYkNKNmVjaTQ5VVFEdUZYVzd1aTlxWUpyUExT?oc=5","date":"2026-04-07","type":"deal","source":"TechStock²","summary":"Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal - TechStock²","headline":"Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal - TechStock²","sentiment":"neutral"},{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOQjJqRnVfMVdLTFhGQV9yaEZZcmJteXZHTnMtdlhuRkNRcnJEdTZlUVdvdlZUemJNQ1M0NEM0VDRrQ0x1NXpnZjJ1M3g4VTNsZ0tKTU1wQy01SFJyYkRMOVJwNzFpdTBrQ0txcll0ZWhCZlhlQUFVTUpyODUxcFRzbG1WSVZrdFMweFJGendSTUpLMUcxTFYxMDktbWo4NDFvVlREWklOVlpHdmtkeGIxSjhwZGJDZTdiTFR5dFRJUTlKWXpQZE1rTmlkYjF2RXUtelc5aDBfdjNIRVRYVkx3OXB1emZRdUE?oc=5","date":"2026-04-06","type":"deal","source":"PR Newswire","summary":"Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PR Newswire","headline":"Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPNzdDNi1YNFVWdWxPUm1XWFlJdTFTdHY4Z0FSQWpyQ2kwUHZ1ZFdNc19XVUxsaDIxV3E1bDJlYVZaV1E5bElGdjl4TnBJeENHV0pvMjhIWGVPUC1ZazZQdW9RMUR6UWNob2hFRDFfMTR1QkdWVW5feERJRThzSk9uWUd6ZTBYVE1NWi1DMW1Wbl83cnFKOFFkaHFoMXhYdF9mZTNEWGVfaEJScW84bG96U3RHY3QxVG5o?oc=5","date":"2026-04-06","type":"deal","source":"Reuters","summary":"Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - Reuters","headline":"Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNQ3NDOEVweWlIQjYzdGZYTlBXWURGOERMZjB4R013OFlaRkpXdzdTa0ZIcVU1NGdCVjJBQ1dXQzRYU2RtM1JlYTFabnhKYXJsd2Vvam1KSkY2QVU1WjNMa3pZeXZuYlJIMGk2TE8wcDMzSUxDWDhXV3FsLVVsQjR6elVOVHBsaEtDOVVkZjdUUVltMnhyVDQ0dVo5SGxwcDNjdUw1Ql9ydGkxdU9tRHh4RXRBSXhhS280M1R6bGtHYkdnT1JxWTNSbXM4Q2JUcWE5?oc=5","date":"2026-04-06","type":"pipeline","source":"proactiveinvestors.com","summary":"Market movers: Virgin Galactic, Soleno Therapeutics, Medicus Pharma... - proactiveinvestors.com","headline":"Market movers: Virgin Galactic, Soleno Therapeutics, Medicus Pharma...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNRDNadXp1cXkzWVRCQlRaMFZfY3dSbENUcE85ZWtwWjZOUko2TmVxcXlZXzJqandqVEZWWGdEMkl3WUZ5VFpjTlJxUWhmak9xdExlMGxKN0V3a05FV25VcTMyeHB4SV9KR0prS0UxU081VWdVMTQwTmgtTnM5bnVKMG9NcWJ1LUFDbjNiSndPZkJJRzlTREtPcjlqc09SNjQ?oc=5","date":"2026-04-06","type":"pipeline","source":"TechStock²","summary":"Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR - TechStock²","headline":"Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR - TechStock²","sentiment":"neutral"},{"date":"2026-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-05","type":"pipeline","source":"simplywall.st","summary":"Do Ongoing DCCR Lawsuits Reframe Soleno Therapeutics’ (SLNO) Risk Profile More Than Its Drug Potential? - simplywall.st","headline":"Do Ongoing DCCR Lawsuits Reframe Soleno Therapeutics’ (SLNO) Risk Profile More Than Its Drug Potential?","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxOcm85dEJpT0Njb0otX3NYeEZHeXcya2Q3Q0NEOXp5dV80QWhPNnlYTlRlMG9QUXRweWhPZEdtZm5qcWF3TnJSSWJha1R3RUstN2dmVlIxZlc4Szhra3J6T09KQWkxLTRHa0dDVTZUdWtLSDUyMmhYMU5HNXo2bllvTm01R2NtNklZNTdESXcyX0F5a19jTmtmbF9DamNxMHNvODVWbW9wWTh2aXUxS0RSckNUbENYVEdzRU1ZTVJuTGlXNHJZNjdLT1lLVXdSd2stX0NwVVJ4MFFRWDlIZDR2OFNqdTJNMkg1aFJBVnNJSkN6VG1jaGZMSk5haklaM19uLXNVWHJzWkE2bGxlWDdPNFRNSWN4ODYwUFZCMFBDamFQNnF6Ny1NRQ?oc=5","date":"2026-03-11","type":"pipeline","source":"GlobeNewswire","summary":"Soleno Therapeutics, Inc. Class Action Notice: Robbins LLP - GlobeNewswire","headline":"Soleno Therapeutics, Inc. Class Action Notice: Robbins LLP","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["United Therapeutics","Pfizer","Novartis"],"therapeuticFocus":["Rare Disease","Endocrinology"],"financials":{"source":"sec_edgar+yahoo","revenue":1450788,"revenuePeriod":"2016-12-31","revenueHistory":[{"value":1450788,"period":"2016-12-31"},{"value":607472,"period":"2015-12-31"},{"value":607472,"period":"2015-12-31"},{"value":0,"period":"2014-12-31"},{"value":3000000,"period":"2013-12-31"}],"grossProfit":187705000,"grossProfitHistory":[{"period":"2025-12-31","value":187705000},{"period":"2024-12-31","value":0},{"period":"2023-12-31","value":0}],"rdSpend":40627000,"rdSpendHistory":[{"period":"2025-12-31","value":40627000},{"period":"2024-12-31","value":78568000},{"period":"2023-12-31","value":25189000},{"period":"2022-12-31","value":15265000}],"sgaSpend":132128000,"operatingIncome":14950000,"operatingIncomeHistory":[{"period":"2025-12-31","value":14950000},{"period":"2024-12-31","value":-184429000},{"period":"2023-12-31","value":-38670000},{"period":"2022-12-31","value":-25109000}],"netIncome":20890000,"netIncomeHistory":[{"period":"2025-12-31","value":20890000},{"period":"2024-12-31","value":-175850000},{"period":"2023-12-31","value":-38988000},{"period":"2022-12-31","value":-24067000}],"eps":0.39,"epsHistory":[{"period":"2025-12-31","value":0.39},{"period":"2024-12-31","value":-4.38},{"period":"2023-12-31","value":-2.36},{"period":"2022-12-31","value":-2.87}],"cash":70106000,"cashHistory":[{"period":"2025-12-31","value":70106000},{"period":"2024-12-31","value":87928000},{"period":"2023-12-31","value":169681000},{"period":"2022-12-31","value":14602000}],"totalAssets":563830000,"totalLiabilities":113715000,"totalDebt":52553000,"equity":450115000,"operatingCashflow":46798000,"operatingCashflowHistory":[{"period":"2025-12-31","value":46798000},{"period":"2024-12-31","value":-69096000},{"period":"2023-12-31","value":-24940000},{"period":"2022-12-31","value":-20781000}],"capex":-73000,"capexHistory":[{"period":"2025-12-31","value":-73000},{"period":"2024-12-31","value":-218000},{"period":"2022-12-31","value":-13000},{"period":"2021-12-31","value":-22000}],"freeCashflow":46725000,"dividendsPaid":null,"buybacks":-100146000,"employees":182,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":40878000,"ebit":44707000,"ebitda":45216000,"period":"2025-12-31","revenue":91730000,"epsBasic":0.82,"netIncome":43358000,"rdExpense":9558000,"epsDiluted":0.8,"grossProfit":90867000,"operatingIncome":40431000},{"sga":33753000,"ebit":27403000,"ebitda":27905000,"period":"2025-09-30","revenue":66018000,"epsBasic":0.49,"netIncome":26013000,"rdExpense":8405000,"epsDiluted":0.47,"grossProfit":64877000,"operatingIncome":22719000},{"sga":28238000,"ebit":-3332000,"ebitda":-2830000,"period":"2025-06-30","revenue":32657000,"epsBasic":-0.09,"netIncome":-4708000,"rdExpense":9147000,"epsDiluted":-0.09,"grossProfit":31961000,"operatingIncome":-5424000},{"sga":29259000,"ebit":-42412000,"ebitda":-41908000,"period":"2025-03-31","revenue":0,"epsBasic":-0.95,"netIncome":-43773000,"rdExpense":13517000,"epsDiluted":-0.95,"grossProfit":null,"operatingIncome":-42776000},{"sga":37303000,"ebit":-49979000,"ebitda":-49476000,"period":"2024-12-31","revenue":0,"epsBasic":-1.27,"netIncome":-55982000,"rdExpense":21486000,"epsDiluted":-1.27,"grossProfit":null,"operatingIncome":-58789000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":52.99,"previousClose":52.95,"fiftyTwoWeekHigh":90.32,"fiftyTwoWeekLow":29.43,"fiftyTwoWeekRange":"29.43 - 90.32","fiftyDayAverage":44.94,"twoHundredDayAverage":52.88,"beta":-2.22,"enterpriseValue":2558439680,"forwardPE":-23.3,"priceToBook":6.16,"priceToSales":9.69,"enterpriseToRevenue":8.98,"enterpriseToEbitda":27.96,"pegRatio":0,"ebitda":91515000,"ebitdaMargin":32.1,"freeCashflow":91667624,"operatingCashflow":105530000,"totalDebt":54277000,"debtToEquity":10.9,"currentRatio":5.62,"returnOnAssets":12.1,"returnOnEquity":26.4,"analystRating":"","recommendationKey":"none","numberOfAnalysts":8,"targetMeanPrice":53,"targetHighPrice":53,"targetLowPrice":53,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.3,"institutionHeldPercent":115.2,"sharesOutstanding":52120147,"floatShares":48555129,"sharesShort":6526389,"shortRatio":1.01,"shortPercentOfFloat":12.5,"epsTrailing":1.93,"epsForward":-2.27,"revenuePerShare":5.45,"bookValue":8.61,"officers":[{"age":55,"name":"Dr. Anish  Bhatnagar M.D.","title":"Chairman, President & CEO"}],"industry":"Biotechnology","irWebsite":"","website":"https://soleno.life","phone":"650 213 8444"}}